What if you'd held PCRX?
A $1,000 investment in Pacira BioSciences, Inc. (PCRX) at the month-end close of 2011-02 would be worth $3,530 at the close of 2026-08 — +253.0% total return, dividends reinvested. The same $1,000 in the S&P 500 would be worth $5,808.
Your scenario
Result
If you'd bought $1,000 at the start of each year
Value of $1,000 invested on January 1 of each year, held to 2026-08, dividends included.
Every year, $1,000 from 2011
| Year | Value of $1,000 | Year return |
|---|---|---|
| 2011 | $1,000 | — |
| 2012 | $2,020 | +102.0% |
| 2013 | $6,646 | +229.1% |
| 2014 | $10,250 | +54.2% |
| 2015 | $8,877 | -13.4% |
| 2016 | $3,734 | -57.9% |
| 2017 | $5,277 | +41.3% |
| 2018 | $4,973 | -5.8% |
| 2019 | $5,237 | +5.3% |
| 2020 | $6,918 | +32.1% |
| 2021 | $6,956 | +0.6% |
| 2022 | $4,464 | -35.8% |
| 2023 | $3,901 | -12.6% |
| 2024 | $2,178 | -44.2% |
| 2025 | $2,992 | +37.4% |
| 2026 | $2,816 | -5.9% |
Best and worst month-end to buy
The best single month-end close to have bought PCRX was 2011-02 ($6.90): $1,000 then is $3,530 today. The worst was 2015-02 ($115): $1,000 then is $212.
FAQ
What would $1,000 in PCRX be worth today?
A $1,000 investment in Pacira BioSciences, Inc. (PCRX) at the start of 2011 would be worth about $3,530 today, a total return of +253.0%. Dividends are reinvested in these figures.
What were the best and worst years for PCRX?
Pacira BioSciences, Inc. (PCRX)'s strongest calendar year since 2011 was 2013, a +229.1% return — $1,000 held through that year became about $3,291 by year-end. Its weakest year was 2016, at -57.9%.
Does the calculator include dividends and splits?
Yes where available. Prices are adjusted for both stock splits and reinvested dividends (total return), the same measure brokerages use.
How much would $100 per month in PCRX have grown?
Investing $100 at the end of every month since 2011-02 would have grown to about $15,472 on $18,700 invested.
Did PCRX beat the S&P 500?
Over the same period, $1,000 in the S&P 500 index would be worth $5,808. PCRX trailed the S&P 500 by +39.2% in total return.
Is this investment advice?
No. Wall Street Regrets is an entertainment and education tool. Every number is a historical calculation, not a prediction, and past performance never guarantees future results.
Methodology
Pacira BioSciences, Inc. (PCRX) historical total-return data from 2011-02 to 2026-08, reduced to month-end closes for the tables above.
Returns use adjusted close prices from Yahoo Finance historical data — adjusted for stock splits and reinvested dividends — the same convention used by major brokerages. A "year" scenario invests $1,000 at the prior December's month-end close and values it at the latest available month-end close. Non-USD amounts are converted at historical month-end exchange rates (Yahoo Finance): to USD on the buy date and back to your currency at the latest rate, so the return reflects the currency move as well as the asset.
Month-end resolution means intra-month extremes are not captured in tables; the calculator uses exact trading-day closes where daily data is available. Figures ignore taxes, fees, and the currency effects of non-USD listings. History is not a forecast. Wall Street Regrets is entertainment, not investment advice.
What if you'd held…
Data: adjusted close prices via Yahoo Finance. As of 2026-08. Not financial advice.